Eli Lilly and Company (NYSE:LLY) Shares Purchased by Congress Asset Management Co. MA

Congress Asset Management Co. MA boosted its position in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 226,503 shares of the company’s stock after purchasing an additional 1,731 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Congress Asset Management Co. MA’s investment portfolio, making the stock its 27th largest position. Congress Asset Management Co. MA’s holdings in Eli Lilly and Company were worth $132,033,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Simon Quick Advisors LLC increased its stake in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares during the last quarter. Independent Advisor Alliance increased its stake in shares of Eli Lilly and Company by 1.7% in the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after acquiring an additional 544 shares during the last quarter. Apexium Financial LP increased its stake in shares of Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after acquiring an additional 10,842 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth $363,000. Finally, Terril Brothers Inc. increased its stake in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after acquiring an additional 429 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a report on Wednesday, February 21st. Argus raised their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Truist Financial raised their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group raised their target price on Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a report on Friday, June 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $787.53.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 75,510 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $860.78, for a total transaction of $64,997,497.80. Following the sale, the insider now directly owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 75,510 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $860.78, for a total value of $64,997,497.80. Following the completion of the transaction, the insider now directly owns 97,793,810 shares of the company’s stock, valued at $84,178,955,771.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 552,804 shares of company stock worth $462,119,714. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $4.88 during midday trading on Friday, hitting $878.45. The company had a trading volume of 2,023,264 shares, compared to its average volume of 2,475,545. The company’s 50 day simple moving average is $785.96 and its 200 day simple moving average is $718.43. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $885.06. The stock has a market cap of $834.88 billion, a price-to-earnings ratio of 129.37, a PEG ratio of 1.93 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the business earned $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.59%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.